What is the pathogenesis of respiratory syncytial virus (RSV) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

RSV Disease Process: Pathogenesis and Mechanisms

RSV is an enveloped, nonsegmented, negative-strand RNA virus of the Paramyxoviridae family that uses attachment (G) and fusion (F) surface glycoproteins to infect respiratory epithelial cells, causing acute inflammation, edema, epithelial cell necrosis, increased mucus production, and bronchospasm in the small airways 1.

Viral Structure and Entry Mechanism

RSV exists as two antigenic subtypes (RSV-A and RSV-B) based on variations in the G protein 2. The virus lacks neuraminidase and hemagglutinin activities, distinguishing it from influenza viruses 1.

The virus enters host cells through:

  • Attachment via the G glycoprotein to respiratory epithelial cell surface receptors
  • Fusion with the host cell membrane mediated by the F protein
  • Direct cell-to-cell spread by inducing fusion of infected cells into multinucleated giant cells (syncytia), which is the hallmark pathological feature 2

Pathophysiological Cascade

Epithelial Damage and Inflammation

Once infection is established, RSV causes:

  • Acute inflammation and edema of epithelial cells lining small airways
  • Necrosis of epithelial cells, leading to airway obstruction
  • Increased mucus production that further compromises airway patency
  • Bronchospasm contributing to wheezing and respiratory distress 3

Immune Response Dysregulation

The severity of RSV disease is largely determined by the host immune response rather than direct viral cytopathic effects 2. The virus employs sophisticated immune evasion strategies:

  • Viral immunomodulatory mechanisms suppress neutrophil, macrophage, and lymphocyte function 4
  • Diminished neutrophil adherence, chemotaxis, phagocytosis, and bactericidal activity increases vulnerability to secondary bacterial infections 4
  • Short-lived immune response: protective antibodies and T cells wane within weeks to months, enabling frequent reinfections even without antigenic variation 2
  • Both antibody and cellular (T-cell) responses are necessary for protection, complicating vaccine development 5

Clinical Manifestations by Anatomic Site

Upper Respiratory Tract Infection (URTI)

RSV initially causes acute upper respiratory tract infection with:

  • Rhinitis
  • Coryza
  • Sore throat
  • Cough 1

Lower Respiratory Tract Disease (LRTD)

A minority of patients progress to lower respiratory tract involvement, characterized by:

  • Bronchiolitis (most common in first infection)
  • Pneumonia
  • Tachypnea
  • Wheezing and crackles
  • Use of accessory muscles
  • Nasal flaring
  • Hypoxia 3

High-Risk Populations and Risk Factors

Characteristics that dramatically increase risk of severe disease include 1:

  • Prematurity (especially <32 weeks gestation)
  • Age <2 months (accounts for 44% of RSV hospitalizations) 5
  • Cyanotic or complicated congenital heart disease causing pulmonary hypertension
  • Chronic lung disease/bronchopulmonary dysplasia
  • Immunocompromised status
  • Elderly patients with cardiopulmonary disease

Long-Term Sequelae

RSV bronchiolitis is associated with persistent respiratory complications:

  • Recurrent wheezing episodes
  • Reactive airway disease
  • Abnormalities in pulmonary function
  • Persistent airflow decline (particularly after infection in first 100 days post-HSCT) 3, 6

Critical caveat: It remains unclear whether severe RSV infection causes these long-term problems or whether children who develop severe bronchiolitis have an underlying predisposition to recurrent wheezing 3.

Transmission Dynamics

RSV spreads through:

  • Large respiratory droplets during close contact with infected persons
  • Indirect contact via RSV-contaminated hands or fomites
  • Portal of entry is typically the conjunctiva or nasal mucosa
  • Infected infants shed large amounts of virus, making them major reservoirs 7

The virus demonstrates seasonal patterns with peak circulation December through March in the Northern Hemisphere, lasting 3-5 months 1, 3.

Reinfection Pattern

Reinfection with RSV throughout life is common and expected 1. Most infants are infected during their first year of life, with virtually all children infected at least once by their second birthday 1. In older children and adults, reinfection typically manifests as upper respiratory tract illness, though severe lower respiratory tract disease can occur in immunocompromised patients and elderly individuals with cardiopulmonary disease 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.